相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome
Takuya Watanabe et al.
ACTA NEUROPATHOLOGICA (2009)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Therapeutic targeting of mTOR in tuberous sclerosis
Julian R. Sampson
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
S. Agarwal et al.
BRITISH JOURNAL OF CANCER (2009)
PI3K/mTORC1 activation in hamartoma syndromes Therapeutic prospects
Vera P. Krymskaya et al.
CELL CYCLE (2009)
Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
Alberto Broniscer et al.
CLINICAL CANCER RESEARCH (2009)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov et al.
CLINICAL CANCER RESEARCH (2009)
Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms
Hrvoje Miletic et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment
Ken Inoki et al.
HUMAN MOLECULAR GENETICS (2009)
IDH1 Mutations at Residue p.R132 (IDH1R132) Occur Frequently in High-Grade Gliomas But Not in Other Solid Tumors
Fonnet E. Bleeker et al.
HUMAN MUTATION (2009)
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Mi Ran Kang et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target
Randy L. Jensen
JOURNAL OF NEURO-ONCOLOGY (2009)
Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies
James L. Frazier et al.
JOURNAL OF NEUROSURGERY-PEDIATRICS (2009)
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas
Tim Forshew et al.
JOURNAL OF PATHOLOGY (2009)
Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1
Hilde Brems et al.
LANCET ONCOLOGY (2009)
Bevacizumab and chemotherapy for recurrent glioblastoma A single-institution experience
P. L. Nghiemphu et al.
NEUROLOGY (2009)
IDH1andIDH2Mutations in Gliomas
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Metabolic Enzymes as Oncogenes or Tumor Suppressors
Craig B. Thompson
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma
D. T. W. Jones et al.
ONCOGENE (2009)
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Andrew S. Chi et al.
ONCOLOGIST (2009)
Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development
Dorine A. Bax et al.
PLOS ONE (2009)
Tumor Stabilization Under Treatment With Imatinib in Progressive Hypothalamic-Chiasmatic Glioma
Andreas Peyrl et al.
PEDIATRIC BLOOD & CANCER (2009)
Objective Response of Multiply Recurrent Low-Grade Gliomas to Bevacizumab and Irinotecan
Roger J. Packer et al.
PEDIATRIC BLOOD & CANCER (2009)
Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/MEK/ERK Pathway
Kwong-Kwok Wong
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
Anja Michalczyk et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
Z. Tang et al.
BRITISH JOURNAL OF CANCER (2008)
Diffuse brainstem gliomas in children: should we or shouldn't we biopsy?
Darren Hargrave
BRITISH JOURNAL OF NEUROSURGERY (2008)
Diffuse brainstem gliomas in children: should we or shouldn't we biopsy?
P. A. Leach et al.
BRITISH JOURNAL OF NEUROSURGERY (2008)
Transient inhibition of the hedgehog pathway in young mice causes permanent defects in bone structure
Hiromichi Kimura et al.
CANCER CELL (2008)
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma
Balazs Hegedus et al.
CANCER RESEARCH (2008)
Temozolomide preferentially depletes cancer stem cells in glioblastoma
Dagmar Beier et al.
CANCER RESEARCH (2008)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
Bret B. Friday et al.
CLINICAL CANCER RESEARCH (2008)
Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas
Halldora K. Thorarinsdottir et al.
CLINICAL CANCER RESEARCH (2008)
Genetics and Molecular Biology of Tuberous Sclerosis Complex
Valerio Napolioni et al.
CURRENT GENOMICS (2008)
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
David A. Reardon et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability
Albert Lai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex
Mary Kay Koenig et al.
JOURNAL OF CHILD NEUROLOGY (2008)
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Stefan Pfister et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma
Marc C. Chamberlain
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric brain tumor consortium study PBTC-012
Tobey J. MacDonald et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study
Regina I. Jakacki et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tyrosine kinase expression in pediatric high grade astrocytoma
Muh-Lii Liang et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma
Eli E. Bar et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases
Sheikh A. Ali et al.
JOURNAL OF NEUROSURGERY (2008)
Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma
Nicole Simonavicius et al.
MODERN PATHOLOGY (2008)
The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners
Margit Rosner et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome
Angela R. Smith et al.
PEDIATRIC BLOOD & CANCER (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme
David Schiff et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model
Veronique Mathieu et al.
NEOPLASIA (2008)
Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors
M. Benesch et al.
ANNALS OF ONCOLOGY (2008)
Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types
T. Hirose et al.
HISTOPATHOLOGY (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Evaluation of HIF-1 inhibitors as anticancer agents
Gregg L. Semenza
DRUG DISCOVERY TODAY (2007)
Making a tumour's bed: glioblastoma stem cells and the vascular niche
Richard J. Gilbertson et al.
NATURE REVIEWS CANCER (2007)
VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells
Naoki Oka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail
David N. Korones
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Microsatellite instability in pediatric and adult high-grade gliomas
Anika Eckert et al.
BRAIN PATHOLOGY (2007)
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
Daniel P. Cahill et al.
CLINICAL CANCER RESEARCH (2007)
Combined treatment with temozolomide and methoxyamine:: Blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIα
Ling Yan et al.
CLINICAL CANCER RESEARCH (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity
Virginie Clement et al.
CURRENT BIOLOGY (2007)
A perivascular niche for brain tumor stem cells
Christopher Calabrese et al.
CANCER CELL (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma
Eli E. Bar et al.
STEM CELLS (2007)
Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations
Robert Listernick et al.
ANNALS OF NEUROLOGY (2007)
Neuro-fibromatosis 1 and neuro-fibromatosis 2: a twenty first century perspective
Rosalie E. Ferner
LANCET NEUROLOGY (2007)
Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array
Kwong-Kwok Wong et al.
CANCER RESEARCH (2006)
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas
Marjut Puputti et al.
MOLECULAR CANCER RESEARCH (2006)
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours
S. Baruchel et al.
EUROPEAN JOURNAL OF CANCER (2006)
The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms
Hariyadarshi Pannu et al.
JOURNAL OF NEUROSURGERY (2006)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors
Xing Fan et al.
CANCER RESEARCH (2006)
O6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas:: Results from the CCG-945 cohort
Ian F. Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
State of the art chemotherapeutic management of pediatric brain tumors
Melissa J. Siegel et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2006)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy
C Hunter et al.
CANCER RESEARCH (2006)
Development of novel therapeutic strategies that target HIF-1
GL Semenza
EXPERT OPINION ON THERAPEUTIC TARGETS (2006)
Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients
BB Freeman et al.
CANCER INVESTIGATION (2006)
Intraturnoral hemorrhage among children with newly diagnosed, diffuse brainstern glioma
A Broniscer et al.
CANCER (2006)
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma
D Koul et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Diffuse brainstem glioma in children: critical review of clinical trials
D Hargrove et al.
LANCET ONCOLOGY (2006)
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
DN Franz et al.
ANNALS OF NEUROLOGY (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pediatric high-grade glioma: Molecular genetic clues for innovative therapeutic approaches
BR Rood et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas
CB Knobbe et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2005)
Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme
H Joensuu et al.
JOURNAL OF PATHOLOGY (2005)
Targeting hypoxia and angiogenesis through HIF-1α inhibition
JA Diaz-Gonzalez et al.
CANCER BIOLOGY & THERAPY (2005)
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A children's oncology group study
NC Daw et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft
CL Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction
L Lafay-Cousin et al.
CANCER (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells
NJ Curtin et al.
CLINICAL CANCER RESEARCH (2004)
Identification of human brain tumour initiating cells
SK Singh et al.
NATURE (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Marked regression of metastatic Pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): A case report and laboratory investigation
ME McLaughlin et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2003)
Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells
M Klingler-Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup study
LS Lashford et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Poly (ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells
L Tentori et al.
GLIA (2002)
Expression of p53 and prognosis in children with malignant gliomas
IF Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The WHO classification of tumors of the nervous system
P Kleihues et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
PAI-1 and EGFR expression in adult glioma tumors: Toward a molecular prognostic classification
X Muracciole et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme
JS Smith et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas
T Sung et al.
BRAIN PATHOLOGY (2000)
Cowden disease and Lhermitte-Duclos disease: Characterization of a new phakomatosis
S Robinson et al.
NEUROSURGERY (2000)
When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre
J Grill et al.
EUROPEAN JOURNAL OF PEDIATRICS (2000)
Incidence of p14(ARF) gene deletion in high-grade adult and pediatric astrocytomas
EW Newcomb et al.
HUMAN PATHOLOGY (2000)
分享论文
